JP2009506301A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009506301A5 JP2009506301A5 JP2008524596A JP2008524596A JP2009506301A5 JP 2009506301 A5 JP2009506301 A5 JP 2009506301A5 JP 2008524596 A JP2008524596 A JP 2008524596A JP 2008524596 A JP2008524596 A JP 2008524596A JP 2009506301 A5 JP2009506301 A5 JP 2009506301A5
- Authority
- JP
- Japan
- Prior art keywords
- pif
- affinity reagent
- abundance
- protein isoform
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0516058.5A GB0516058D0 (en) | 2005-08-04 | 2005-08-04 | New protein isoforms and uses thereof |
| US72208705P | 2005-09-30 | 2005-09-30 | |
| PCT/GB2006/050232 WO2007015113A2 (en) | 2005-08-04 | 2006-08-04 | New protein isoforms of the pif-family and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009506301A JP2009506301A (ja) | 2009-02-12 |
| JP2009506301A5 true JP2009506301A5 (https=) | 2009-09-17 |
Family
ID=34984093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008524596A Pending JP2009506301A (ja) | 2005-08-04 | 2006-08-04 | Ｐｉｆファミリーの新たなタンパク質アイソフォーム及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100223678A1 (https=) |
| EP (1) | EP1987356A2 (https=) |
| JP (1) | JP2009506301A (https=) |
| GB (1) | GB0516058D0 (https=) |
| WO (1) | WO2007015113A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2444695T3 (es) | 2006-06-23 | 2014-02-26 | Alethia Biotherapeutics Inc. | Polinucleótidos y polipéptidos implicados en el cáncer |
| CA2740900C (en) | 2008-11-03 | 2019-09-24 | Alethia Biotherapeutics Inc. | Antibodies that specifically block the biological activity of a tumor antigen |
| WO2010096331A1 (en) | 2009-02-11 | 2010-08-26 | Duke University | Sensors incorporating antibodies and methods of making and using the same |
| JP5433341B2 (ja) * | 2009-08-04 | 2014-03-05 | ホーユー株式会社 | 等電点電気泳動方法及び粗雑物除去の判定方法 |
| JP5190423B2 (ja) * | 2009-08-04 | 2013-04-24 | ホーユー株式会社 | ２次元電気泳動方法 |
| SI3173427T1 (sl) | 2011-03-31 | 2019-08-30 | ADC Therapeutics SA, | Protitelesa proti antigenu 1, povezanemu z ledvicami, in antigen vezavni fragmenti le-tega |
| WO2013030032A1 (en) * | 2011-08-26 | 2013-03-07 | F. Hoffmann-La Roche Ag | A method for predicting clinical benefit in the treatment of neurodevelopmental, neurological or neuropsychiatric disorders |
| KR102102239B1 (ko) | 2012-01-09 | 2020-04-21 | 에이디씨 테라퓨틱스 에스에이 | 유방암을 치료하기 위한 방법 |
| US9244946B2 (en) | 2012-11-26 | 2016-01-26 | International Business Machines Corporation | Data mining shape based data |
| WO2015187227A2 (en) | 2014-03-13 | 2015-12-10 | Duke University | Electronic platform for sensing and control of electrochemical reactions |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6319687B1 (en) * | 1992-09-24 | 2001-11-20 | The United States Of America As Represented By The Department Of Health And Human Services | Pigment epithelium-derived factor: characterization, genomic organization and sequence of PEDF gene |
| US6613740B1 (en) * | 1997-02-07 | 2003-09-02 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Activity dependent neurotrophic factor III (ADNF III) |
| US20040038877A1 (en) * | 2001-10-02 | 2004-02-26 | Alsobrook John P. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| JP2003284574A (ja) * | 2001-10-03 | 2003-10-07 | Pfizer Prod Inc | 核酸分子、ポリペプチド、ならびにアルツハイマー病の診断および処置を含むそれらの使用 |
| AU2003235789A1 (en) * | 2002-01-11 | 2003-07-24 | Xantos Biomedicine Ag | Novel apoptosis-inducing dna sequences |
| WO2005014645A2 (en) * | 2003-08-07 | 2005-02-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pedf-r receptor and uses |
| JP2005132738A (ja) * | 2003-10-28 | 2005-05-26 | Protein Express:Kk | アルツハイマー病のタンパク質分子レベルにおける検出方法 |
-
2005
- 2005-08-04 GB GBGB0516058.5A patent/GB0516058D0/en not_active Ceased
-
2006
- 2006-08-04 WO PCT/GB2006/050232 patent/WO2007015113A2/en not_active Ceased
- 2006-08-04 EP EP06765380A patent/EP1987356A2/en not_active Withdrawn
- 2006-08-04 US US11/989,828 patent/US20100223678A1/en not_active Abandoned
- 2006-08-04 JP JP2008524596A patent/JP2009506301A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Laroche et al. | Diagnostic value of histamine and tryptase concentrations in severe anaphylaxis with shock or cardiac arrest during anesthesia | |
| Ohtsuka et al. | Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging | |
| US20140303041A1 (en) | In vitro diagnostic devices for nervous system injury and other neural disorders | |
| Bowser et al. | Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations | |
| Hanly et al. | Anti-NR2 glutamate receptor antibodies and cognitive function in systemic lupus erythematosus. | |
| EP3115785A2 (en) | Process to diagnose or treat brain injury | |
| CN107533048A (zh) | 用于诊断脑损伤或神经退行性变的方法和组合物 | |
| US20220057409A1 (en) | Combinatorial temporal biomarkers and precision medicines with detection and treatment methods for use in neuro injury, neuro disease, and neuro repair | |
| Castaneyra-Ruiz et al. | Cerebrospinal fluid levels of tumor necrosis factor alpha and aquaporin 1 in patients with mild cognitive impairment and idiopathic normal pressure hydrocephalus | |
| Nigro et al. | Magnetic Resonance Parkinsonism Index and midbrain to pons ratio: Which index better distinguishes Progressive Supranuclear Palsy patients with a low degree of diagnostic certainty from patients with Parkinson Disease? | |
| KR20230010687A (ko) | 알츠하이머 병 평가용 단백질 마커 | |
| KR20170062478A (ko) | 우울증 치료약의 선택지를 예측하는 방법 | |
| JP2018132526A (ja) | 大うつ病性障害及び双極性障害のマーカー、検査方法、検査キット、及び治療薬のスクリーニング方法。 | |
| González-Quevedo et al. | Increased serum S-100B and neuron specific enolase—Potential markers of early nervous system involvement in essential hypertension | |
| JP2009506301A5 (https=) | ||
| Blandford et al. | Interleukin-1 receptor antagonist: an exploratory plasma biomarker that correlates with disability and provides pathophysiological insights in relapsing-remitting multiple sclerosis | |
| JP5267452B2 (ja) | 精神障害および／または腸のディスバイオシスのインビトロまたはエクスビボ診断方法 | |
| JP5295101B2 (ja) | 神経変性疾患の経過及び予後の評価指標を提供するｉｎｖｉｔｒｏ方法 | |
| US7709215B2 (en) | Method for diagnosing and treating acute joint injury | |
| JP7808340B2 (ja) | 軽度認知障害検査 | |
| Li et al. | Increased level of procalcitonin is associated with total MRI burden of cerebral small vessel disease in patients with ischemic stroke | |
| US20060205024A1 (en) | Method to diagnose and evaluate progression of Alzheimer's disease | |
| Khodjieva et al. | Correlation between neuroimaging, neurological deficits, and neurotrophic proteins in predicting rehabilitation potential in ischemic stroke patients | |
| EP2802879B1 (en) | Use of ccl23 as brain damage marker | |
| CN103210312A (zh) | 通过软骨酸性蛋白1 检测脑梗塞的方法 |